Market news

Natera (NASDAQ:NTRA) has outperformed the market over the past 5 years by 17.64% on an annualized basis producing an average annual return of 29.65%. Currently, Natera has a market capitalization of $59.35 billion.

CNBC’s Final Trades: Rob Sechan picks Hewlett Packard, Kevin Simpson favors Natera, and Stephen Weiss recommends UnitedHealth.

Natera (NTRA) has an average rating of overweight and mean price target of $352.80, according to ana

NTRA wins Japan PMDA approval for Signatera in muscle-invasive bladder cancer, supporting treatment decisions and a planned 2027 commercial launch.

Detailed price information for Lennar Corp (LEN-N) from The Globe and Mail including charting and trades.

Detailed price information for Natera Inc (NTRA-Q) from The Globe and Mail including charting and trades.

Natera and its collaborators recently presented four abstracts at the IASLC 2026 World Conference on Lung Cancer, including the largest molecular residual disease dataset to date in resected stage 1–3 non-small cell lung cancer, showing that Signatera status after surgery is strongly associated with recurrence-free survival and overall survival. An important insight from these data is that Signatera-positive patients had around five times the risk of recurrence or death during surveillance,...

The sale was executed under a pre-arranged Rule 10b5-1 plan amended in March 2026, leaving Chapman with 98,199 directly held shares.

The well-respected investor has Meta Platforms, Delta Air Lines, and Eli Lilly in his family office's portfolio. The stock isn't one of those.

Motley Fool Press Release.

Matthew Rabinowitz, Director, Executive Chairman, on September 11, 2026, sold 50,000 shares in Nater

Natera, Inc. (NASDAQ:NTRA) is expanding across oncology, women’s health and organ transplantation, but Jim Cramer says the stock’s valuation has become difficult to justify after a sharp rally. During the September 3 episode of Mad Money, he said, “It is an intriguing story.” He called it “a precision medicine platform,” as he advised investors to […]

Natera (NTRA) has an average rating of buy and mean price target of $344.33, according to analysts p

His largest position today is a bet on genomics.

AUSTIN, Texas, September 01, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signatera in patients with both newly diagnosed and relapsed/refractory (R/R) lymphoma.

NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.

AUSTIN, Texas, August 28, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a national partnership with Susan G. Komen®, the world’s leading breast cancer organization. Together, the organizations aim to accelerate breast cancer awareness and education, including efforts to increase understanding of MRD. Natera’s SignateraTM MRD test is supported by more than 185 peer-reviewed publications across multiple cancer types, including b

Natera recently announced a collaboration with Kupando Therapeutics to supply its Latitude tissue-free MRD assay for a Phase 1 immunotherapy trial in multiple skin cancers, expanding the use of its technology in oncology research. At the same time, Duquesne Family Office significantly increased its position in Natera, making the diagnostics company its largest healthcare holding and underscoring rising institutional interest in its MRD and medtech platform. Now we’ll explore how this...

AUSTIN, Texas, August 27, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new Signatera collaboration with Angiex, Inc., a privately held biotech company developing a portfolio of Nuclear-Delivered Antibody-Drug Conjugates™ (ND-ADCs).

Natera (NTRA) has launched a new Signatera collaboration with Angiex, which is a privately held biot

Natera (NasdaqGS:NTRA) announced a collaboration with Kupando Therapeutics to supply its Latitude tissue-free MRD assay for a Phase 1 immunotherapy trial in multiple skin cancers. The Latitude assay will be used to monitor minimal residual disease and treatment response in patients receiving Kupando's investigational therapy. The partnership expands Natera's presence in oncology clinical trials and supports use of its MRD technology across different tumor types. This kind of cancer trial...

Natera’s Signatera drives rapid growth with Medicare coverage and key regulatory wins, but looks overvalued vs. peers. Read more on NTRA stock here.

Natera's growth, expanding role in cancer care, and growing diagnostic data platform help explain why Druckenmiller has made it a major portfolio holding, despite valuation and regulatory risks.

Natera (NTRA) stock analysis: despite 37.7% Q2 revenue growth, valuation looks stretched. Read here for a detailed investment analysis.

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks fared in Q2, starting with Natera (NASDAQ:NTRA).

NTRA is using its Latitude MRD test in Kupando's Phase 1 skin cancer trial to track ctDNA and characterize response to KUP-101.

Natera (NTRA) has drawn fresh attention after announcing a new collaboration that puts its Latitude molecular residual disease test into a Phase 1 clinical trial for Kupando Therapeutics’ lead immunotherapy candidate, KUP-101. See our latest analysis for Natera. The latest collaboration news comes after an active stretch for Natera, with recent earnings, raised 2026 revenue guidance and regulatory milestones in Japan helping underpin strong momentum. The stock’s share price return of 60.97%...